藥物成份

共有 21645 個藥物成份

Leukocytes：0.5% w/w derivatized pyrrole amino acid ester；0.4% w/w diazonium salt；32% w/w buffer；67.1% w/w non-reactive ingredients

• 關聯藥證數量: 1

Leuprolide Mesylate contains not less than 97.0 percent and not more than 103.0 percent of C59H84N16O12•(CH4O3S)n，n=1.5 to 1.8 calculated on anhydrous and methanesulfonic acid-free basis.

• 關聯藥證數量: 1

Leuprolide mesylate

• 關聯藥證數量: 1

Levamisole

• 關聯藥證數量: 1

Levamisole hydrochloride contains not less than 98.5% and not more than the equivalent of 101.0% of (6S)-6-phenyl-2,3,5,6-tetrahydroimidazo﹝2,1-b﹞thiazole hydrochloride, calculated with reference to the dried substance.

• 關聯藥證數量: 1

Level 1 59 μmol/L (100μg/dL) 1 mg/L Ammonium Sulphate Level 2 118μmol/L (200μg/dL) 2 mg/L Ammonium Sulphate Level 3 177μmol/L (300μg/dL) 3 mg/L Ammonium Sulphate

• 關聯藥證數量: 1

Level 1, 2, 3 component: Lyophilized Citrated plasma.

• 關聯藥證數量: 1

Level 1: human urine, 150 ng/mL methylenedioxymethamphetamine (MDMA), preservative\nLevel 2: human urine, 300 ng/mL methylenedioxymethamphetamine (MDMA), preservative\nLevel 3: human urine, 500 ng/mL methylenedioxymethamphetamine (MDMA), preservative\nLevel 4: human urine, 1000 ng/mL methylenedioxymethamphetamine (MDMA), preservative\n

• 關聯藥證數量: 1

Level 1: prepared from human serum with human and nonhuman proteins and non-protein constituents added.\nAlbumin, Bicarbonate (CO2), Direct Bilirubin, Total Bilirubin, Calcium, Iron.\nLevel 2: prepared from human serum with human and nonhuman proteins and non-protein constituents added.\nBicarbonate(CO2), Calcium, Cholesterol, Creatinine, Glucoes, Inorganic Phosphorus, \nMagnesium, Total Protein, Triglyceride, Unsaturated Iron Binding Capacity(UIBC), Urea Nitrogen(BUN), Uric Acid.

• 關聯藥證數量: 1

Level 1: processed human urine containing alpha-1-microglobulin, albumin, transferrin and IgGLevel 2: processed human urine containing alpha-1-microglobulin, albumin, transferrin and IgG

• 關聯藥證數量: 1

Level I\nControl Particles: 0.01%、\nEthanol: 9.8%、\nHydrochloric acid: 0.2%、\nLevel II\nControl Particels: 0.2%、\nEthanol: 9.6%、\nHydrochloric acid: 0.4%、\nLevel III\nControl Particles: 1.1%、\nEthanol: 9.4%、\nHydrochloric acid: 0.5%

• 關聯藥證數量: 1

Levetiracetam Content: 98.0% ~ 102.0% (anhydrous substance) of C8H14N2O2

• 關聯藥證數量: 1

Levetiracetam contains NLT 98.0% and NMT 102.0% of C8H14N2O2, calculated on the anhydrous and solvent-free basis.

• 關聯藥證數量: 1

Levetiracetam contains not less than 98.0% and not more than 102.0% of C8H14N2O2 calculated on the anhydrous and solvent-free basis.

• 關聯藥證數量: 1

Levetiracetam contains not less than 98.0% and not more than 102.0% of C8H14N2O2, calculated on anhydrous basis.

• 關聯藥證數量: 1

Levetiracetam contains not less than 98.0% and not more than 102.0% of C8H14N2O2, calculated on the anhydrous and solvent-free basis..

• 關聯藥證數量: 1

Levetiracetam contains not less than 98.0% and not more than 102.0% of C8H14N2O2, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Levetiracetam contains not less than 98.0% and not more than 102.0% of C8H14N2O2, calculated on the anhydrous substance.

• 關聯藥證數量: 1

Levocarnitine contains NLT 98.0% and NMT 102.0% of levocarnitine (C7H15NO3), calculated on the anhydrous basis.

• 關聯藥證數量: 1

Levocarnitine contains NLT 98.0%~102.0% of C7H15NO3 anhydrous base.

• 關聯藥證數量: 1

Levocarnitine contains not less than 98.0% and not more than 102.0% of C7H15NO3, calculated on anhydrous substance.

• 關聯藥證數量: 1

Levocarnitine contains not less than 98.0% and not more than 102.0% of C7H15NO3, calculated on the dried basis.

• 關聯藥證數量: 1

Levocetirizine Dihydrochloride contains 99.0%~101.0% (anhydrous substance) of C21H27Cl3N2O3

• 關聯藥證數量: 1

Levocetirizine Dihydrochloride contains NLT 98.0% and NMT 102.0% of Levocetirizine Dihydrochloride (C21H25ClN2O3‧2HCl), calculated on the dried basis.

• 關聯藥證數量: 1

Levocetirizine Dihydrochloride contains NLT 98.0% and NMT 102.0% of Levocetirizine Dihydrochloride (C21H25ClN2O3‧2HCl), calculated on the dried basis.

• 關聯藥證數量: 1

Levocetirizine Dihydrochloride contains not less than 98.0 % and not more than 102.0 % of C21H25ClN2O3‧2HCl, calculated on the dried basis.

• 關聯藥證數量: 1

Levocetirizine Dihydrochloride contains not less than 98.0 % and not more than 102.0 % of levocetirizine dihydrochloride (C21H25ClN2O3‧2HCl), calculated on the dried basis.

• 關聯藥證數量: 1

Levocetirizine Dihydrochloride contains not less than 98.0% and not more than 102.0% of C21H25ClN2O3.2HCl calculated on the dried basis.

• 關聯藥證數量: 1

Levocetirizine Dihydrochloride contains not less than 99.0% and not more than 100.5% of C21H27Cl3N2O3, calculated on the dried basis.

• 關聯藥證數量: 1

Levocetirizine Dihydrochloride contains not less than 99.0% and not more than 101.0% of C2H27Cl3N2O3, calculated on dried basis.

• 關聯藥證數量: 1

Levodopa contains not less than 98.0 percent and not more than 102.0 percent of C9H11NO4, calculated on the dried basis.

• 關聯藥證數量: 1

Levodopa contains not less than 99.0% and not more than 101.0% of C9H11NO4, calculated on the dried substance.

• 關聯藥證數量: 1

Levodopa contains: 99.0% to 101.0% (dried substance).

• 關聯藥證數量: 1

Levodopa(L-dopa; L-Dihydroxyphenylalanine), when dried, contains not less than 99.0 percent and not more than 100.5 percent of Levodopa (C9H11NO4).

• 關聯藥證數量: 1

Levofloxacin Hemihydrate contains NLT 98.0% and NMT 102.0% of C18H20FN3O4, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Levofloxacin Hemihydrate contains not less than 98.0% and not more than 101.0% of C18H20FN3O4, 1/2H2O, calculated on the anhydrous substance.

• 關聯藥證數量: 1

Levofloxacin Hemihydrate contains not less than 98.0% and not more than 102.0% of C18H20FN3O4, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Levofloxacin Hemihydrate contains not less than 98.0% and not more than 102.0% of C18H20FN3O4‧1/2H2O, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Levofloxacin Hemihydrate contains not less than 99.0% and not more than 101.0% of levofloxacin(C18H20FN3O4), calculated on the anhydrous basis.

• 關聯藥證數量: 1

Levofloxacin contains not less than 98.5% and not more than 102.0% of C18H20FN3O4, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Levofloxacin contains not less than 98.5%~102.0% of C18H20FN3O4 calculated on the anhydrous basis.

• 關聯藥證數量: 1

Levonorgestrel contains 98.0~102.0% (as dried basis)

• 關聯藥證數量: 1

Levonorgestrel contains not less than 98.0 percent and not more than 102.0 percent of C21H28O2, calculated on the dried basis.

• 關聯藥證數量: 1

Levonorgestrel contains not less than 98.0% and not more than 102.0% of C21H28O2, calculated on the dried basis.

• 關聯藥證數量: 1

Levonorgestrel contains not less than 98.0% and not more than the equivalent of 102.0% of C21H28O2, calculated with reference to the dried substance.

• 關聯藥證數量: 1

Levonorgestrel micronized

• 關聯藥證數量: 1

Lidocaine (Base)\nContains not less than 97.5% and not more than 102.5%.

• 關聯藥證數量: 1

Lidocaine HCL contains not less than 99.0% and not more than 101.0% on anhydrous basis.

• 關聯藥證數量: 1

Lidocaine HCl contains not less than 97.5% and not more than 102.5% of C14H22N2O？HCl. , calculated on the anhydrous.

• 關聯藥證數量: 1

Lidocaine Hydrochloride contains 99.0 per cent to 101.0 per cent (anhydrous substance) of C14H23ClN2O,H2O

• 關聯藥證數量: 1

Lidocaine Hydrochloride contains 99.0% to 101.0% (anhydrous substance)

• 關聯藥證數量: 1

Lidocaine contains 99.0% to 101.0% (anhydrous substance)

• 關聯藥證數量: 1

Lidocaine contains 99.0% to 101.0% (anhydrous substance) of C14H22N2O.

• 關聯藥證數量: 1

Lidocaine contains not less than 97.5% and not more than 102.5% of C14H22N2O.

• 關聯藥證數量: 1

Lidocaine contains not less than 99.0% and not more than 101.0% on anhydrous basis.

• 關聯藥證數量: 1

Lifitegrast

• 關聯藥證數量: 1

LightCycler 2.0 InstrumentLightCycler Desktop Datastation. Barcode Reader for LightCycler 2.0 Instruments.LC Carousel Centrifuge 2.0.

• 關聯藥證數量: 1

Limaprost Alfadex 2.8% ~ 3.2% (anhydrous basis)

• 關聯藥證數量: 1

Limonene, Hydrocarbons

• 關聯藥證數量: 1

Linagliptin (Form-C) contains NLT 98.0% and NMT 102.0% of C25H28N8O2, calculated on anhydrous substance.

• 關聯藥證數量: 1

Linagliptin contains NLT 98.0% and NMT 102.0% of C25H28N8O2, calculated on anhydrous basis.

• 關聯藥證數量: 1

Linagliptin contains not less than 98% and not more than 102.0% of C25H28N8O2, calculated on anhydrous basis.

• 關聯藥證數量: 1

Linagliptin contains not less than 98.0% and not more than 102.0% of C25H28N8O2, calculated on anhydrous basis.

• 關聯藥證數量: 1

Linagliptin contains not less than 98.0% and not more than 102.0% of C25H28N8O2, calculated on the dried basis.

• 關聯藥證數量: 1

Linagliptin contains not less than 98.0% and not more than 102.0%, calculated on the dried basis.

• 關聯藥證數量: 1

Linalyl Acetate

• 關聯藥證數量: 1

Lincomycin Hydrochloride contains -sum of the contents of lincomycin hydrochloride and lincomycin B hydrochloride：96.0 per cent to 102.0 per cent (anhydrous substance)； - lincomycin B hydrochloride：maximum 5.0 per cent (anhydrous substance)。

• 關聯藥證數量: 1

Lincomycin Hydrochloride contains not less than 82.5% of C18H34N2O5S, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Lincomycin Hydrochloride contains not less than 82.5% of C18H34N2O6S,Hcl H2O, calculated on the dried basis.

• 關聯藥證數量: 1

Lincomycin Hydrochloride contains not less than 89.5% and not more than 102.0% of C18H34N2O6 S.HCL.H2O, calculated on the dried basis.

• 關聯藥證數量: 1

Lincomycin Hydrochloride contains not less than 89.5% and not more than 102.0% of C18H35ClN2O6S.H2O

• 關聯藥證數量: 1

Lincomycin Hydrochloride contains-sum of the contents of lincomycin hydrochloride and lincomycin B hydrochloride : 96.0% to 102.0% (anhydrous substance) ; - lincomycin B hydrochloride : maximum 5.0% (anhydrous substance)。

• 關聯藥證數量: 1

Linezolid contains 98.0%~102.0% (as dried basis)

• 關聯藥證數量: 1

Lipase 93 U/LAdenosine triphosphate (ATP) 2.52 mmol/LGlycerol kinase (GK) 4 KIU/LGlycerophosphate oxidase (GPO) 1.1 KIU/L4-Aminoantipyrine 0.71 mmol/L3,5-Dichloro-2-Hydroxybenzenesulfonic acid (DHBS) 1.54 mmol/LHorseradish peroxidase (HPO) 9 KIU/L

• 關聯藥證數量: 1

Lipegfilgrastim

• 關聯藥證數量: 1

Lipid Calibrator is prepared by lyophilizing pooled human sera containing an appropriate amount of lipids.

• 關聯藥證數量: 1

Lipoprotein Lipase, ATP, Glycerol kinase, Glycerol-3-Phosphate-oxidase, 4-aminoantipyrine, 4-chlorophenol, Peroxidase, Mg2+, and Buffer

• 關聯藥證數量: 1

Lipoprotein lipase(LPL)

• 關聯藥證數量: 1

Liquichek ToRCH Plus IgM Control, Positive is prepared from negative human serum based material with mouse monoclonal antibodies conjugated to non-specific human IgM molecules for each analyte tested. The positive control also contains constituents of animal origin and preservatives.

• 關聯藥證數量: 1

Liquid animal sera produced by immunization of rabbits with highly purified human RbP

• 關聯藥證數量: 1

Liquid antinal sera produced by immunization of rabbits with highly purified human haptoglobin.

• 關聯藥證數量: 1

Liquid, ready-for-use control materials based on juman serum with assayed values for all important serum proteins in the normal and abnormal range.

• 關聯藥證數量: 1

Liquimmune® is a liquid stable control material prepared from human serum. Analyte levels are adjusted with various pure chemicals and preparations from human tissue or body fluids. Prostate specific antigen is from human seminal fluid, alpha-fetoprotein is from human cord serum and carcinoembryonic antigen is from hepatic metastases of human colon adenocarcinoma. Preservatives and stabilizers are added to maintain product integrity.

• 關聯藥證數量: 1

Lisinopril (2S)-1-[(2S)-6-Amino-2-[[(1S)-1-carboxy-3-phenylpropyl]-amino]hexanoyl]pyrrolidine-2-carboxylic acid dihydrate. Content: 98.5 per cent to 101.5 per cent (anhydrous substance).

• 關聯藥證數量: 1

Lisinopril Dihydrate(Anhydride Process) contains not less than 98.5% and not more than 101.5% of C21H31N3O5．2H2O), calculated on the anhydrous substance.

• 關聯藥證數量: 1

Lisinopril contains not less than 98.0% and not more than 102.0% of C21H31N3O5, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Lite reagent: T. gondii antigen (~1.05μg/mL) complexed with an anti-p30 monoclonal labeled with acridinium ester in protein buffer with surfactant and preservatives\nSolid phase: anti-human IgGFc monoclonal antibody (~0.3 mg/mL) covalently coupled to paramagnetic particles in protein buffer with surfactant and preservatives\nCalibrators: processed human plasma positive for toxoplasma IgG antibodies with preservatives\nControls: processed human plasma negative and positive for toxoplasma IgG antibodies with preservatives\n

• 關聯藥證數量: 1

Lite reagent: T. gondii antigen (~3μg/mL) complexed with an anti-p30 monoclonal labeled with acridinium ester in protein buffer with surfactant and preservatives\nSolid phase: anti-human IgMμ monoclonal antibody (~24 μg/mL) covalently coupled to paramagnetic particles in protein buffer with surfactant and preservatives\nCalibrators: processed human plasma positive for toxoplasma IgM antibodies with preservatives\nControls: processed human plasma negative and positive for toxoplasma IgM antibodies with preservatives\n

• 關聯藥證數量: 1

Lite reagent: acridinium ester-labeled phenobarbital (~302 pg/mL) in buffer with preservatives\nSolid phase: monoclonal mouse anti-phenobarbital antibody (~4μg/mL) covalently coupled to paramagnetic particles in buffer with preservatives\nReleasing agent: 0.2M CAPS buffer preservatives\nCalibrator: low and high levels of phenobarbital in human plasma with sodium azide (<0.1%) and preservatives\n \n

• 關聯藥證數量: 1

Lite reagent: gentamicin derivative labeled with acridinium ester (~0.46 ng/mL) in phosphate buffer with BSA, sodium azide (<0.1%), and preservatives\nSolid phase: monoclonal mouse anti-gentamicin antibody (~20μg/mL) covalently coupled to paramagnetic particles in phosphate buffered saline with BSA, sodium azide (<0.1%), and preservatives\nProbe Wash 2: 0.2N hydrochloric acid\nCalibrator: after reconstitution, low and high levels of gentamicin in human serum with sodium azide (<0.1%) \n

• 關聯藥證數量: 1

Lite reagent: inactivated rubella virus antigen (strain HPV77) (~0.20μg/mL) labeled with acridinium ester in protein buffer with surfactant and preservatives\nSolid phase: anti-human IgGFc monoclonal antibody (~0.15 mg/mL) covalently coupled to paramagnetic particles in protein buffer with preservatives\nCalibrators: processed human plasma positive for rubella IgG antibodies with preservatives\nControls: processed human plasma negative and positive for rubella IgG antibodies with preservatives\n

• 關聯藥證數量: 1

Lite reagent: inactivated rubella virus antigen (strain HPV77) (~0.27μg/mL) labeled with acridinium ester in buffer with preservatives\nSolid phase: anti-human IgMμ monoclonal antibody (~0.14 mg/mL) covalently coupled to paramagnetic particles in buffer with preservatives\nCalibrators: processed human plasma positive for rubella IgM antibodies with preservatives\nControls: processed human plasma negative and positive for rubella IgM antibodies with preservatives\n \n

• 關聯藥證數量: 1

Lite reagent: monoclonal mouse anti-digitoxin antibody (~60 ng/mL) labeled with acridinium ester in buffer with protein stabilizers, sodium azide (<0.1%), and preservatives\nSolid phase: digoxin (~3.4μg/mL) covalently coupled to paramagnetic particles in buffer with protein stabilizers, sodium azide (<0.1%), and preservatives\n

• 關聯藥證數量: 1

Lite reagent: monoclonal mouse anti-human BNP F(ab’)2 fragment antibody (~0.025μg/mL) labeled with acridinium ester in buffer with bovine gamma globulin, mouse gamma globulin and preservatives\nSolid phase: monoclonal mouse anti-human BNP antibody (~1.25μg/mL) in bovine gamma globulin, mouse gamma globulin and preservatives\nCalibrator: after reconstitution, low or high levels of synthetic human BNP in lyophilized buffered sodium caseinate with sodium azide (<0.1%)\nQC: various levels of synthetic human BNP in lyophilized buffered sodium caseinate with sodium azide (<0.1%)\n

• 關聯藥證數量: 1

Lite reagent: monoclonal mouse anti-human HER-2/neu antibody (~1.8μg/mL) labeled with acridinium ester in phosphate buffer with bovine serum albumin and sodium azide (<0.1%)Solid phase: monoclonal mouse anti-fluorescein antibody (~30μg/mL) coupled to paramagnetic particles in phosphate buffer with bovine serum albumin and sodium azide (<0.1%)Fluorescein conjugate reagent: monoclonal mouse anti-human HER-2/neu antibody (~7.0μg/mL) labeled with fluorescein in PIPES buffer with bovine serum albumin and sodium azide (<0.1%)Calibrator: low or high levels of HER-2/neu in bovine serum with sodium azide (<0.1%)QC: low and high levels of HER-2/neu in bovine serum with sodium azide (<0.1%)

• 關聯藥證數量: 1

Lite reagent: polyclonal goat anti-PSA antibody (~77 ng/mL) labeled with acridinium ester in buffered saline with bovine serum albumin and preservatives \nSolid phase: monoclonal mouse anti-PSA antibody (~25μg/mL) covalently coupled to paramagnetic particles in buffered saline with bovine serum albumin and preservatives\nPretreatment: free-PSA-specific monoclonal mouse anti-PSA antibody (~50μg/mL) in buffered saline with bovine serum albumin and preservatives \nCalibrator: after reconstitution, low or high levels of complexed PSA in goat serum with sodium azide (<0.1%) and preservatives \nQC: after reconstitution, various levels of complexed PSA in goat serum with sodium azide (<0.1%) and preservatives \n

• 關聯藥證數量: 1

Lite reagent: theophylline labeled with acridinium ester (~0.3 ng/mL) in buffered saline with bovine serum albumin and sodium azide (<0.1%)\nSolid phase: monoclonal mouse anti-theophylline antibody (~3 μg/mL) bound to monoclonal mouse capture antibody (~14μg/mL) covalently coupled to paramagnetic particles in buffered saline with bovine serum albumin and sodium azide (<0.1%) \nCalibrators: low or high levels of theophylline in human plasma with sodium azide (0.2% after reconstitution), preservatives, and protein stabilizers\n

• 關聯藥證數量: 1

Lite reagent: tobramycin (~0.16 ng/mL) labeled with acridinium ester in buffered saline with sodium azide (<0.1%), and preservatives\nSolid phase: monoclonal mouse anti-tobramycin antibody (~16μg/mL) covalently coupled to paramagnetic particles in buffered saline with sodium azide (<0.1%), and preservatives\n

• 關聯藥證數量: 1

Lite reagent: valproic acid (~0.2 ng/mL) labeled with acridinium ester in phosphate buffered saline with bovine serum albumin, bovine gamma globulin, and preservatives\nSolid phase: monoclonal mouse anti-valproic acid antibody (~6.7μg/mL) coupled to paramagnetic particles in phosphate buffered saline with bovine serum albumin, bovine gamma globulin, and preservatives\nCalibrator: after reconstitution, low or high levels of valproic acid in human plasma with sodium azide (<0.1%) and preservatives\n

• 關聯藥證數量: 1

Lite reagent: vancomycin (~6 ng/mL) coupled to bovine serum albumin labeled with acridinium ester in buffered saline with sodium azide (<0.1%) and preservatives\nSolid phase: monoclonal mouse anti-vancomycin (~6.7 μg/mL) covalently coupled to paramagnetic particles in buffered saline with sodium azide (<0.1%) and preservatives\nCalibrators: after reconstitution, low or high levels of vancomycin in human serum with sodium azide (<0.1%) and preservatives\n

• 關聯藥證數量: 1